

J M Schattenberg

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4418448/j-m-schattenberg-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

168
papers

6,283
citations

41
h-index

75
g-index

215
ext. papers

9,683
ext. citations

6.2
avg, IF

6.21
L-index

#	Paper	IF	Citations
168	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020 , 73, 202-209	13.4	764
167	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018 , 69, 896-904	13.4	550
166	JNK1 but not JNK2 promotes the development of steatohepatitis in mice. <i>Hepatology</i> , 2006 , 43, 163-72	11.2	306
165	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 740-751	0.7	273
164	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020 , 158, 1611-1625.e12	13.3	234
163	Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28 Suppl 1, 68-76	4	170
162	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021 , 592, 450-456	50.4	164
161	Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. <i>Journal of Biological Chemistry</i> , 2005 , 280, 9887-94	5.4	153
160	Animal models of non-alcoholic steatohepatitis: of mice and man. <i>Digestive Diseases</i> , 2010 , 28, 247-54	3.2	114
159	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113
158	Liver injury in COVID-19: The current evidence. <i>United European Gastroenterology Journal</i> , 2020 , 8, 509-519	3.9	108
157	Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. <i>Journal of Lipid Research</i> , 2017 , 58, 247-255	6.3	108
156	Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019 , 69, 2241-2257	11.2	107
155	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. <i>Journal of Hepatology</i> , 2020 , 72, 816-827	13.4	88
154	Apoptosis in liver disease. <i>Liver International</i> , 2006 , 26, 904-11	7.9	87
153	Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. <i>Current Opinion in Lipidology</i> , 2011 , 22, 479-88	4.4	86
152	Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26 Suppl 1, 213-9	4	85

151	Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. <i>BMC Cancer</i> , 2012 , 12, 109	4.8	77
150	Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. <i>Gut</i> , 2016 , 65, 1564-71	19.2	75
149	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 728-735.e4	6.9	73
148	Hepatocyte resistance to oxidative stress is dependent on protein kinase C-mediated down-regulation of c-Jun/AP-1. <i>Journal of Biological Chemistry</i> , 2004 , 279, 31089-97	5.4	64
147	Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation. <i>Journal of Hepatology</i> , 2018 , 68, 986-995	13.4	62
146	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019 , 68, 1099-1107	19.2	62
145	Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. <i>BMC Cancer</i> , 2015 , 15, 210	4.8	62
144	Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. <i>Hepatology</i> , 2005 , 42, 1072-81	11.2	62
143	CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. <i>Hepatology</i> , 2004 , 39, 444-55	11.2	60
142	Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?. <i>Gastroenterology</i> , 2020 , 158, 1929-1947.e6	13.3	59
141	Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. <i>Oncology Reports</i> , 2006 , 15, 227-30	3.5	58
140	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. <i>Gut</i> , 2022 , 71, 156-162	19.2	56
139	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1109-1116	6.1	53
138	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. <i>Diabetologia</i> , 2017 , 60, 1873-1882	10.3	51
137	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
136	Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo. <i>Journal of Hepatology</i> , 2011 , 55, 1272-80	13.4	50
135	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021 , 385, 1547-1558	59.2	50
134	Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 297, G907-17	5.1	49

133	Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. <i>Transplant International</i> , 2013 , 26, 67-74	3	48
132	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019 , 1, 188-198	10.3	46
131	Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw011	1	45
130	Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling. <i>Redox Biology</i> , 2014 , 3, 7-15	11.3	45
129	Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2012 , 54, 93-5	14.5	44
128	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2085-2092.e1	6.9	41
127	NAFLD - sounding the alarm on a silent epidemic. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 377-379	24.2	41
126	Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 313-321	6.1	39
125	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
124	Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 930-939	6.1	36
123	Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. <i>International Journal of Oncology</i> , 2013 , 42, 1297-304	4.4	35
122	Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2112-2119	4	35
121	Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. <i>Journal of Hepatology</i> , 2020 , 73, 680-693	13.4	32
120	Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. <i>BMC Cancer</i> , 2016 , 16, 94	4.8	32
119	Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. <i>Digestive and Liver Disease</i> , 2016 , 48, 291-7	3.3	31
118	Diabetes and apoptosis: liver. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009 , 14, 1459-71	5.4	30
117	Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. <i>Hepatology Communications</i> , 2020 , 4, 1293-1301	6	29
116	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 781-793	18.8	29

115	Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells. <i>Cell Death and Disease</i> , 2013 , 4, e712	9.8	27
114	Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. <i>Journal of Human Genetics</i> , 2018 , 63, 621-626	4.3	25
113	Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. <i>European Journal of Internal Medicine</i> , 2011 , 22, 305-10 ^{3.9}	3.9	25
112	Clinical Frailty Scale for risk stratification in patients with SARS-CoV-2 infection. <i>Journal of Investigative Medicine</i> , 2020 , 68, 1199-1202	2.9	22
111	Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 303, G498-506	5.1	22
110	Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. <i>United European Gastroenterology Journal</i> , 2020 , 8, 942-948	5.3	21
109	Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 764-770	0.7	21
108	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020 , 2, 100143	143	20
107	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021 , 41, 1227-1242	7.9	20
106	Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. <i>International Journal of Cardiology</i> , 2018 , 271, 296-300	3.2	19
105	Health-related quality of life in patients with compensated and decompensated liver cirrhosis. <i>European Journal of Internal Medicine</i> , 2019 , 70, 54-59	3.9	18
104	Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. <i>BMC Gastroenterology</i> , 2015 , 15, 97	3	18
103	Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. <i>Hepatology Communications</i> , 2019 , 3, 1472-1481	6	18
102	The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1365-1375	5.9	18
101	Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD. <i>Scientific Reports</i> , 2019 , 9, 4007	4.9	17
100	Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). <i>European Journal of Internal Medicine</i> , 2010 , 21, 208-15	3.9	17
99	The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2016 , 11, e0151200	3.7	16
98	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021 , 74, 474-482	11.2	16

97	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 717-729	24.2	16
96	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. <i>Journal of Hepatology</i> , 2021 , 74, 1344-1354	13.4	16
95	The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs. <i>Frontiers in Medicine</i> , 2019 , 6, 61	4.9	15
94	Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGF β Signaling and Promote Colitis. <i>Gastroenterology</i> , 2019 , 156, 692-707.e7	13.3	15
93	The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. <i>Free Radical Biology and Medicine</i> , 2012 , 52, 1911-7	7.8	14
92	Risk factors in patients with rapid recurrent hepatitis C virus-related cirrhosis within 1 year after liver transplantation. <i>Transplantation Proceedings</i> , 2009 , 41, 2549-56	1.1	14
91	Elevated levels of Bcl-3 inhibits Treg development and function resulting in spontaneous colitis. <i>Nature Communications</i> , 2017 , 8, 15069	17.4	13
90	Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Nutrients</i> , 2020 , 12,	6.7	13
89	Patterns of liver injury in COVID-19 - a German case series. <i>United European Gastroenterology Journal</i> , 2020 , 8, 814-819	5.3	13
88	Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 527-536	6.1	12
87	Epidemiology of hepatic encephalopathy in german hospitals - the EpHE study. <i>Zeitschrift Fur Gastroenterologie</i> , 2017 , 55, 741-747	1.6	12
86	Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. <i>Oncotarget</i> , 2017 , 8, 115667-115680	3.3	12
85	Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2019 , 9, 17463	4.9	12
84	Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy. <i>European Journal of Internal Medicine</i> , 2019 , 60, 96-100	3.9	12
83	Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, e303-e307	3	11
82	Applicability of a Web-Based, Individualized Exercise Intervention in Patients With Liver Disease, Cystic Fibrosis, Esophageal Cancer, and Psychiatric Disorders: Process Evaluation of 4 Ongoing Clinical Trials. <i>JMIR Research Protocols</i> , 2018 , 7, e106	2	11
81	Acute organ failure following the loss of anti-apoptotic cellular FLICE-inhibitory protein involves activation of innate immune receptors. <i>Cell Death and Differentiation</i> , 2015 , 22, 826-37	12.7	10
80	New onset of diabetes after transplantation is associated with improved patient survival after liver transplantation due to confounding factor. <i>European Journal of Internal Medicine</i> , 2015 , 26, 439-44	3.9	10

79	Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors. <i>Journal of Hepatology</i> , 2016 , 65, 1188-1197	13.4	10
78	Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieu. <i>Cell Death and Disease</i> , 2017 , 8, e2893	9.8	10
77	Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 314, G319-G333	5.1	10
76	A novel device for intracolonscopy cleansing of inadequately prepared colonoscopy patients: a feasibility study. <i>Endoscopy</i> , 2019 , 51, 85-92	3.4	9
75	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015 , 141, 515-22	4.9	9
74	Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study. <i>Journal of Medical Internet Research</i> , 2019 , 21, e11250	7.6	9
73	Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1112-1119	6.1	8
72	Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease. <i>Deutsches A&#x0308;rzblatt International</i> , 2020 , 117, 719-724	2.5	8
71	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2021 ,	11.2	8
70	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 974-986	3.4	7
69	Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. <i>Digestive and Liver Disease</i> , 2014 , 46, 67-71	3.3	7
68	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. <i>Journal of Hepatology</i> , 2017 , 66, S593	13.4	7
67	Disclosure behaviour and experienced reactions in patients with HIV versus chronic viral hepatitis or diabetes mellitus in Germany. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013 , 25, 1259-70	2.2	7
66	Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF- κ B activation. <i>Oncotarget</i> , 2017 , 8, 56095-56109	3.3	7
65	The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. <i>JHEP Reports</i> , 2020 , 2, 100168	10.3	7
64	Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseases. <i>Autoimmunity Reviews</i> , 2021 , 20, 102706	13.6	7
63	Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021 , 28, 1235-1241	8.6	7
62	Leptomeningeal familial amyloidosis: A rare differential diagnosis of leptomeningeal enhancement in MRI. <i>Journal of Neurology</i> , 2006 , 253, 1238-40	5.5	6

61	Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 3179-3185	4	6
60	Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. <i>Nutrients</i> , 2021 , 13,	6.7	6
59	Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?. <i>Hepatology Communications</i> , 2020 , 4, 141-144	6	5
58	Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. <i>European Journal of Internal Medicine</i> , 2018 , 55, 57-65	3.9	5
57	Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma--a report of 2 cases. <i>Oncology Research and Treatment</i> , 2014 , 37, 674-7	2.8	5
56	Response: Frailty assessment in the COVID-19 pandemic. <i>Journal of Investigative Medicine</i> , 2020 , 68, 1302.9		5
55	Nonalcoholic Fatty Liver Disease in 2020. <i>Gastroenterology</i> , 2020 , 158, 1849-1850	13.3	5
54	Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis. <i>JHEP Reports</i> , 2021 , 3, 100317	10.3	5
53	Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. <i>BMC Gastroenterology</i> , 2017 , 17, 26	3	4
52	Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Digestive Diseases</i> , 2018 , 36, 78-88	3.2	4
51	Assessing the disease burden of non-alcoholic fatty liver disease in the real world - big data and big numbers. <i>BMC Medicine</i> , 2019 , 17, 123	11.4	4
50	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , 2022 , 4, 100409	10.3	4
49	TNF/TNF Receptors 2010 , 161-177		4
48	Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC). <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3006-3013	4	4
47	Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1042-1050	6.1	4
46	NAFLD in the Elderly. <i>Clinical Interventions in Aging</i> , 2021 , 16, 1633-1649	4	4
45	Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.. <i>Biomedicines</i> , 2021 , 9,	4.8	4
44	The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm. <i>Hepatology</i> , 2017 , 66, 666-667	11.2	3

43	A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2020 , 58, 57-62	1.6	3
42	Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives. <i>Health and Quality of Life Outcomes</i> , 2020 , 18, 10	3	3
41	On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020 , 73, 1592-1593	13.4	3
40	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 1253-1266	4.2	3
39	Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis. <i>Visceral Medicine</i> , 2020 , 36, 411-416	4.6	2
38	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. <i>Liver International</i> , 2020 , 40, 2660	7.9	2
37	Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort. <i>Zeitschrift Fur Gastroenterologie</i> , 2020 , 58, 30-38	1.6	2
36	Serological diagnosis of early HCC in NASH: A German multicenter study. <i>Journal of Hepatology</i> , 2018 , 68, S421-S422	13.4	2
35	TNF signaling 2015 , 186-202		2
34	Shortcut to death. <i>Hepatology</i> , 2009 , 50, 2040-3	11.2	2
33	Show me your signaling--and I'll tell you who you are. <i>Journal of Hepatology</i> , 2009 , 51, 638-9	13.4	2
32	Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany.. <i>Hepatology Communications</i> , 2022 ,	6	2
31	Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease. <i>United European Gastroenterology Journal</i> , 2021 , 9, 903-909	5.3	2
30	Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care. <i>PLoS ONE</i> , 2021 , 16, e0249347	2.7	2
29	The gut microbiota instructs the hepatic endothelial cell transcriptome. <i>iScience</i> , 2021 , 24, 103092	6.1	2
28	Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion. <i>Zeitschrift Fur Gastroenterologie</i> , 2021 , 59, 43-49	1.6	2
27	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. <i>JHEP Reports</i> , 2022 , 4, 100477	10.3	2
26	Transforming Growth Factor- β -Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome.. <i>Cancers</i> , 2022 , 14,	6.6	1

25	Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. AuthorsP reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 673	6.1	1
24	Impact of non-selective β blockers on hepatic encephalopathy in patients with liver cirrhosis. <i>European Journal of Internal Medicine</i> , 2020 , 82, 83-89	3.9	1
23	Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis. <i>JHEP Reports</i> , 2020 , 2, 100081	10.3	1
22	Intestinal motility: a therapeutic target for NAFLD?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 957-958	18.8	1
21	Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-the role for non-invasive testing. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 214-215	6.1	1
20	Risk factors for poorer health literacy in patients with liver cirrhosis. <i>PLoS ONE</i> , 2021 , 16, e0255349	3.7	1
19	NAFLD between genes and environment: what drives fibrogenesis?. <i>Gut</i> , 2021 , 70, 815-816	19.2	1
18	Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 247-253	2.2	1
17	Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany. <i>United European Gastroenterology Journal</i> , 2021 , 9, 829	5.3	1
16	Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 1065-1078	3.8	1
15	Hepatic sarcoidosis: Clinical characteristics and outcome. <i>JHEP Reports</i> , 2021 , 3, 100360	10.3	1
14	Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis.. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022 , 101873	2.4	0
13	Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?. <i>Journal of Hepatology</i> , 2020 , 73, 1285-1287	13.4	0
12	Health-related quality of life in patients with autoimmune hepatitis. <i>Quality of Life Research</i> , 2021 , 30, 2853-2861	3.7	0
11	Derzeit bleiben als Gegenmittel nur Aufmerksamkeit und Lebensstilmodifikation. <i>Info Diabetologie</i> , 2015 , 9, 28-32	0	
10	Differenzialdiagnose der Fettlebererkrankung. <i>Gastroenterologe</i> , 2020 , 15, 88-95	0.1	
9	Predictors of the Metabolic Syndrome after Orthotopic Liver Transplantation Identified by a Retrospective Analysis. <i>Transplantation</i> , 2012 , 94, 673	1.8	
8	Prädiktion fortgeschrittener Fibrose bei Patienten mit nicht-alkoholischer Fettleber (NAFLD) □ Vergleich von NAFLD fibrosis score (NFS), Fibrosis-4 (Fib-4) score und APRI. <i>Zeitschrift Fur Gastroenterologie</i> , 2016 , 54, 1343-1404	1.6	

- | | | |
|---|--|------|
| 7 | Presence of the MBOAT7 rs641738 variant might enhance liver fibrosis in patients with fatty liver: analysis of the German NAFLD CSG cohort. <i>Zeitschrift Fur Gastroenterologie</i> , 2016 , 54, 1343-1404 | 1.6 |
| 6 | Generation and functional analyses of hepatocyte-specific type I interleukin-1 receptor (IL-1RI) knockout mice. <i>Zeitschrift Fur Gastroenterologie</i> , 2016 , 54, 1343-1404 | 1.6 |
| 5 | Neue diagnostische Methoden für Patienten mit Diabetes und Fettleber. <i>Diabetologe</i> , 2020 , 16, 566-572 | 0.2 |
| 4 | In Reply. <i>Deutsches Arzteblatt International</i> , 2021 , 118, 271-272 | 2.5 |
| 3 | Fruktose – Freund oder Feind?. <i>Aktuelle Ernährungsmedizin Klinik Und Praxis</i> , 2016 , 41, 388-402 | 0.3 |
| 2 | Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit. <i>Gut</i> , 2020 , 69, 1377-1378 | 19.2 |
| 1 | Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis. <i>Diagnostics</i> , 2022 , 12, 1069 | 3.8 |